Brief: Synthaverse Gets Poland's GIF Decision Extending Manufacturing For New Immunological Products Facility
21/08/2026 08:18
BRIEF-Synthaverse Gets Poland's GIF Decision Extending Manufacturing For New Immunological Products Facility Aug 21 (Reuters) - Synthaverse SA SVEP.WA:
GETS POLAND'S CHIEF PHARMACEUTICAL INSPECTORATE DECISION EXTENDING MANUFACTURING AUTHORISATION FOR NEW IMMUNOLOGICAL PRODUCTS FACILITY
PERMIT EXTENSION ENABLES CONTINUING PROCESS TO LAUNCH PRODUCTION OF ONKO BCG AND BCG TUBERCULOSIS VACCINE AT NEW PLANT
EXPECTS TO REACH READINESS FOR COMMERCIAL MANUFACTURING AT NEW FACILITY AT TURN OF 2027 AND 2028
Source text: ID:nEM59BGZ1a
Further company coverage: SVEP.WA
(Reporting by Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Synthaverse SA
See all newsBrief: Synthaverse EGM To Vote On Share Capital Increase Via Series X Share Issue
Brief: Synthaverse Gets 45 Mln Zloty Loan From Polish Agency For Enterprise Development For Debt Refinancing
Brief: Synthaverse Receives Registration Certificate For Onko BCG Product In Paraguay Under Partnership With Blau
Brief: Synthaverse H1 Net Loss At 6.4 Mln Zlotys
Brief: Synthaverse Gets Poland's GIF Decision Extending Manufacturing For New Immunological Products Facility